InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,231.60
(
-0.14%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
-0.72%
)
Bitcoin
64,138.38
(
-1.05%
)
Post# of 462037
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

abew4me

Send PM Follow Ignore
Followers 43
Posts 4885
Boards Moderated 0
Alias Born 04/30/2005

abew4me

Re: Investor2014 post# 427234

Monday, 08/14/2023 2:30:41 PM

Monday, August 14, 2023 2:30:41 PM

Post# of 462037
Yes it most certainly is.

Once A2-73 has obtained FDA approval for Rett, that is the disease the FDA has assigned to that drug.

Therefore, if Anavex plans to submit an NDA using A2-73 for Fragile X (or any other disease) without conducting a P1 or P2, then they are in fact repurposing that drug.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AVXL News
More AVXL News
InvestorsHub NewsWire

Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM

ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM

North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM

VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM

Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM

Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM

Start posting your company's news
Only $200 per official company press release!